menu
Making successful Targeted Alpha Therapy a reality
Orano Med seeks to develop a new generation of targeted therapies against cancer using the unique properties of lead-212 (212Pb), a rare alpha-emitting radioisotope and one of the most potent therapeutic payloads against cancer cells.
200
Employees in France and the United States
2
Preclinical laboratories dedicated to the development of alpha therapies
1
Industrial production platform for lead-212
2
Ongoing clinical trials
12
Patented inventions
+30%
growth of the radioligand therapy market